Sol-Gel’s Patidegib Gel Nears Key Milestone With Completed Phase 3 Gorlin Syndrome Study
TipRanks (Fri, 18-Sep 12:30 PM ET)
Sol-Gel Technologies Reaches Last-Patient Milestone in Phase 3 Gorlin Syndrome Trial
TipRanks (Thu, 17-Sep 9:17 AM ET)
Globe Newswire (Thu, 17-Sep 8:30 AM ET)
Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Globe Newswire (Thu, 20-Aug 8:30 AM ET)
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.
Sol-Gel Technologies Ltd. - trades on the NASDAQ stock market under the symbol SLGL.
As of September 18, 2026, SLGL stock price declined to $60.00 with 44,511 million shares trading.
SLGL has a beta of 0.71, meaning it tends to be less sensitive to market movements. SLGL has a correlation of 0.02 to the broad based SPY ETF.
SLGL has a market cap of $194.72 million. This is considered a Micro Cap stock.
Last quarter Sol-Gel Technologies Ltd. - reported $591,000 in Revenue and -$1.13 earnings per share. This beat revenue expectation by $441,000 and exceeded earnings estimates by $1.18.
In the last 3 years, SLGL traded as high as $97.97 and as low as $3.34.
The top ETF exchange traded funds that SLGL belongs to (by Net Assets): IZRL, QQQS.
SLGL has outperformed the market in the last year with a return of +125.8%, while the SPY ETF gained +16.8%. However, in the most recent history, SLGL shares have underperformed the stock market with its stock returning -19.4% in the last 3 month period and -13.7% for the last 2 week period, while SPY has returned +2.3% and -0.9%, respectively.
SLGL support price is $60.87 and resistance is $68.22 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SLGL shares will trade within this expected range on the day.
